IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES WITH REVEFENACIN FOR NEBULIZATION IN WOMEN VS MEN WITH MODERATE TO VERY SEVERE COPD: SUBGROUP ANALYSES FROM PHASE 3 CLINICAL TRIALS